Share Price and Basic Stock Data
Last Updated: December 5, 2025, 7:44 pm
| PEG Ratio | 0.12 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cravatex Ltd operates within the trading and distribution sector, primarily focusing on sporting and fitness products. As of now, the company’s market capitalization stands at ₹98.0 Cr, with its share price at ₹380. Over the last few quarters, Cravatex has faced significant revenue fluctuations. For instance, its sales dropped sharply from ₹162.40 Cr in June 2022 to just ₹56.60 Cr by June 2023, indicating a concerning downward trend. The company recorded a marginal recovery with sales of ₹57.45 Cr in September 2023, but this still represents a stark decline from its previous performance. This volatility raises questions about the company’s sales strategies and market positioning, especially as it heads into a period of historically lower revenue, as seen in its projected sales of ₹25.78 Cr in June 2024. Investors might find it worrisome that the company has not yet established a consistent upward trajectory in revenue growth, which is critical for long-term sustainability.
Profitability and Efficiency Metrics
Profitability remains a pressing concern for Cravatex, as evidenced by its negative operating profit margins over several quarters. The company’s operating profit margin (OPM) stood at a bleak -26.42% in the trailing twelve months, reflecting ongoing challenges in controlling costs relative to sales. Notably, net profits have also fluctuated, with a reported net profit of just ₹3 Cr for FY 2025. While the company has shown some resilience with a return on equity (ROE) of 4.68% and a return on capital employed (ROCE) of 6.57%, these figures are relatively low and suggest that Cravatex is not utilizing its capital efficiently compared to sector standards. The interest coverage ratio of 20.39x indicates that the company can comfortably cover its interest obligations, but the overall profitability metrics reveal a business struggling to convert sales into actual profit, which could deter potential investors.
Balance Sheet Strength and Financial Ratios
Cravatex’s balance sheet presents a mixed picture. On one hand, the company boasts no borrowings, which is a significant strength, allowing it to maintain a debt-free status that can be appealing to conservative investors. The reserves have increased to ₹104 Cr, reflecting an accumulation of retained earnings. However, the price-to-book value ratio of 0.83x suggests that the stock may be undervalued relative to its book value, potentially indicating market skepticism about future growth prospects. The current ratio at 4.22x suggests a strong liquidity position, indicating that Cravatex can meet its short-term obligations without difficulty. However, the declining trend in sales and profitability metrics raises questions about the sustainability of these financial strengths. Investors need to weigh these strengths against the backdrop of a challenging operating environment that has seen profitability metrics dwindle.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cravatex reflects a stable structure, with promoters holding a substantial 75% stake in the company. This high level of promoter ownership can instill confidence among retail investors, as it suggests that the management team is heavily invested in the company’s success. The public shareholding stands at 25%, representing a diverse base of retail investors. The number of shareholders has gradually increased, from 1,775 in March 2023 to 2,456 by June 2025, indicating growing interest in the stock despite its recent challenges. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could raise concerns about broader market confidence in Cravatex. The absence of institutional backing might suggest that larger investors are cautious, which could impact liquidity and stock performance going forward.
Outlook, Risks, and Final Insight
Looking ahead, Cravatex’s outlook hinges on its ability to stabilize revenue and improve profitability. The company faces several risks, including ongoing volatility in sales and a lack of institutional support, which could limit its growth potential. Additionally, the significant drop in sales over the past year raises concerns about its market strategy and competitive positioning. Investors should closely monitor the company’s efforts to control costs and enhance operational efficiency, as these will be critical for any turnaround. While the strong liquidity and lack of debt may provide some cushion, the persistent profitability challenges suggest that the stock may remain under pressure in the near future. A cautious approach is advisable for potential investors, who should weigh the risks against the strengths in Cravatex’s financial position. As always, thorough due diligence will be essential in navigating the complexities of this stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Cravatex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 64.3 Cr. | 3.35 | 5.59/3.20 | 42.9 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 13.0 Cr. | 14.7 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 5.94 Cr. | 65.3 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 103 Cr. | 50.4 | 54.5/10.2 | 115 | 15.1 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 107 Cr. | 96.0 | 174/84.4 | 15.1 | 30.6 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 11,033.45 Cr | 161.57 | 90.12 | 120.92 | 0.40% | 15.37% | 8.86% | 7.74 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 162.40 | 170.42 | 87.10 | 83.74 | 56.60 | 57.45 | 37.90 | 50.68 | 25.78 | 55.04 | 32.43 | 60.52 | 23.13 |
| Expenses | 166.43 | 176.91 | 103.63 | 87.03 | 56.42 | 59.62 | 41.69 | 52.56 | 28.11 | 53.03 | 34.30 | 60.01 | 29.24 |
| Operating Profit | -4.03 | -6.49 | -16.53 | -3.29 | 0.18 | -2.17 | -3.79 | -1.88 | -2.33 | 2.01 | -1.87 | 0.51 | -6.11 |
| OPM % | -2.48% | -3.81% | -18.98% | -3.93% | 0.32% | -3.78% | -10.00% | -3.71% | -9.04% | 3.65% | -5.77% | 0.84% | -26.42% |
| Other Income | 1.50 | 2.52 | 107.57 | 6.59 | 1.58 | 6.03 | 5.82 | 2.68 | 3.48 | 2.14 | 2.24 | 2.09 | 5.21 |
| Interest | 3.69 | 4.86 | 3.51 | 1.31 | 0.08 | 0.08 | 0.13 | 0.11 | 0.11 | 0.11 | 0.11 | 0.09 | 0.09 |
| Depreciation | 3.94 | 8.85 | 2.91 | 0.44 | 0.47 | 0.53 | 0.49 | 0.39 | 0.34 | 0.34 | 0.40 | 0.40 | 0.38 |
| Profit before tax | -10.16 | -17.68 | 84.62 | 1.55 | 1.21 | 3.25 | 1.41 | 0.30 | 0.70 | 3.70 | -0.14 | 2.11 | -1.37 |
| Tax % | 9.25% | 8.54% | -0.90% | -147.74% | 64.46% | 4.00% | 43.97% | -70.00% | 30.00% | 28.38% | -278.57% | 31.75% | 0.73% |
| Net Profit | -11.11 | -19.18 | 85.38 | 3.84 | 0.42 | 3.11 | 0.79 | 0.50 | 0.48 | 2.65 | 0.25 | 1.44 | -1.37 |
| EPS in Rs | -42.99 | -74.22 | 330.39 | 14.86 | 1.63 | 12.03 | 3.06 | 1.93 | 1.86 | 10.25 | 0.97 | 5.57 | -5.30 |
Last Updated: August 19, 2025, 8:35 pm
Below is a detailed analysis of the quarterly data for Cravatex Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.13 Cr.. The value appears to be declining and may need further review. It has decreased from 60.52 Cr. (Mar 2025) to 23.13 Cr., marking a decrease of 37.39 Cr..
- For Expenses, as of Jun 2025, the value is 29.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 60.01 Cr. (Mar 2025) to 29.24 Cr., marking a decrease of 30.77 Cr..
- For Operating Profit, as of Jun 2025, the value is -6.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.51 Cr. (Mar 2025) to -6.11 Cr., marking a decrease of 6.62 Cr..
- For OPM %, as of Jun 2025, the value is -26.42%. The value appears to be declining and may need further review. It has decreased from 0.84% (Mar 2025) to -26.42%, marking a decrease of 27.26%.
- For Other Income, as of Jun 2025, the value is 5.21 Cr.. The value appears strong and on an upward trend. It has increased from 2.09 Cr. (Mar 2025) to 5.21 Cr., marking an increase of 3.12 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.40 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 2.11 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 3.48 Cr..
- For Tax %, as of Jun 2025, the value is 0.73%. The value appears to be improving (decreasing) as expected. It has decreased from 31.75% (Mar 2025) to 0.73%, marking a decrease of 31.02%.
- For Net Profit, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 1.44 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 2.81 Cr..
- For EPS in Rs, as of Jun 2025, the value is -5.30. The value appears to be declining and may need further review. It has decreased from 5.57 (Mar 2025) to -5.30, marking a decrease of 10.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 8:03 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 244 | 232 | 255 | 266 | 356 | 718 | 865 | 532 | 594 | 504 | 203 | 174 | 171 |
| Expenses | 230 | 218 | 249 | 271 | 361 | 694 | 843 | 543 | 592 | 533 | 210 | 175 | 177 |
| Operating Profit | 13 | 14 | 6 | -5 | -6 | 24 | 21 | -11 | 2 | -30 | -8 | -2 | -5 |
| OPM % | 5% | 6% | 2% | -2% | -2% | 3% | 2% | -2% | 0% | -6% | -4% | -1% | -3% |
| Other Income | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 13 | 10 | 118 | 16 | 10 | 12 |
| Interest | 8 | 10 | 13 | 11 | 5 | 6 | 14 | 15 | 14 | 14 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 3 | 3 | 6 | 6 | 15 | 17 | 16 | 16 | 2 | 1 | 2 |
| Profit before tax | 7 | 3 | -7 | -15 | -12 | 17 | -2 | -30 | -19 | 58 | 6 | 6 | 4 |
| Tax % | 27% | 28% | 8% | -9% | 2% | 37% | 95% | 3% | 7% | -1% | 22% | 24% | |
| Net Profit | 5 | 2 | -8 | -14 | -12 | 11 | -5 | -31 | -20 | 59 | 5 | 5 | 3 |
| EPS in Rs | 18.88 | 9.25 | -30.65 | -53.67 | -47.75 | 41.25 | -18.23 | -118.45 | -76.97 | 228.04 | 18.69 | 18.69 | 11.49 |
| Dividend Payout % | 18% | 22% | 0% | 0% | -2% | 5% | -16% | -3% | -4% | 1% | 16% | 67% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -60.00% | -500.00% | -75.00% | 14.29% | 191.67% | -145.45% | -520.00% | 35.48% | 395.00% | -91.53% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -440.00% | 425.00% | 89.29% | 177.38% | -337.12% | -374.55% | 555.48% | 359.52% | -486.53% | 91.53% |
Cravatex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -27% |
| 3 Years: | -34% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | -39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 4% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -16% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:06 pm
Balance Sheet
Last Updated: July 25, 2025, 1:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 40 | 41 | 33 | 19 | 7 | 17 | -4 | -31 | -52 | 90 | 96 | 104 |
| Borrowings | 67 | 66 | 72 | 135 | 105 | 117 | 202 | 155 | 167 | 0 | 0 | 0 |
| Other Liabilities | 51 | 54 | 67 | 63 | 94 | 163 | 241 | 259 | 247 | 44 | 26 | 34 |
| Total Liabilities | 160 | 164 | 175 | 220 | 208 | 299 | 442 | 385 | 365 | 137 | 125 | 141 |
| Fixed Assets | 29 | 29 | 28 | 53 | 48 | 48 | 92 | 76 | 62 | 8 | 9 | 9 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 | 1 | 25 | 15 | 5 | 5 | 8 | 16 |
| Other Assets | 131 | 135 | 147 | 167 | 155 | 250 | 325 | 294 | 298 | 124 | 108 | 116 |
| Total Assets | 160 | 164 | 175 | 220 | 208 | 299 | 442 | 385 | 365 | 137 | 125 | 141 |
Below is a detailed analysis of the balance sheet data for Cravatex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 104.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 8.00 Cr..
- For Other Assets, as of Mar 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 108.00 Cr. (Mar 2024) to 116.00 Cr., marking an increase of 8.00 Cr..
- For Total Assets, as of Mar 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (104.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -54.00 | -52.00 | -66.00 | -140.00 | -111.00 | -93.00 | -181.00 | -166.00 | -165.00 | -30.00 | -8.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 113 | 115 | 106 | 84 | 106 | 76 | 72 | 98 | 82 | 19 | 25 | 50 |
| Inventory Days | 87 | 124 | 124 | 84 | 53 | 60 | 49 | 85 | 84 | 29 | 28 | 40 |
| Days Payable | 61 | 66 | 71 | 65 | 89 | 16 | 25 | 23 | 36 | 21 | 25 | 43 |
| Cash Conversion Cycle | 139 | 173 | 159 | 102 | 70 | 120 | 95 | 160 | 130 | 27 | 28 | 47 |
| Working Capital Days | 35 | 42 | 20 | -4 | 40 | 27 | 10 | 24 | 29 | 16 | 15 | 19 |
| ROCE % | 15% | 12% | 5% | -3% | -6% | 18% | 6% | -6% | -2% | -24% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Diluted EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Cash EPS (Rs.) | 24.40 | 25.97 | 290.52 | -13.62 | -50.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Revenue From Operations / Share (Rs.) | 672.41 | 784.12 | 1948.99 | 2299.88 | 2058.19 |
| PBDIT / Share (Rs.) | 31.94 | 32.66 | -69.16 | 43.74 | 7.78 |
| PBIT / Share (Rs.) | 26.22 | 25.37 | -131.63 | -19.60 | -59.71 |
| PBT / Share (Rs.) | 24.66 | 23.84 | 225.73 | -71.76 | -115.13 |
| Net Profit / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| NP After MI And SOA / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.95 | -118.45 |
| PBDIT Margin (%) | 4.75 | 4.16 | -3.54 | 1.90 | 0.37 |
| PBIT Margin (%) | 3.90 | 3.23 | -6.75 | -0.85 | -2.90 |
| PBT Margin (%) | 3.66 | 3.04 | 11.58 | -3.12 | -5.59 |
| Net Profit Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| NP After MI And SOA Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| Return on Networth / Equity (%) | 4.53 | 4.89 | 63.80 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 6.18 | 6.42 | -36.18 | -3.18 | -9.16 |
| Return On Assets (%) | 3.43 | 3.87 | 43.12 | -5.45 | -7.94 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -2.14 | -2.98 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -3.36 | -5.47 |
| Asset Turnover Ratio (%) | 1.31 | 1.55 | 0.01 | 0.01 | 0.01 |
| Current Ratio (X) | 4.22 | 5.11 | 2.95 | 1.43 | 1.39 |
| Quick Ratio (X) | 3.86 | 4.64 | 2.27 | 0.97 | 1.00 |
| Inventory Turnover Ratio (X) | 15.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.39 | 21.30 | -1.34 | 0.83 | 0.14 |
| Interest Coverage Ratio (Post Tax) (X) | 12.93 | 13.18 | -2.50 | -0.47 | -1.14 |
| Enterprise Value (Cr.) | 13.09 | 36.92 | 26.37 | 297.69 | 268.76 |
| EV / Net Operating Revenue (X) | 0.07 | 0.18 | 0.05 | 0.50 | 0.50 |
| EV / EBITDA (X) | 1.59 | 4.37 | -1.48 | 26.34 | 133.65 |
| MarketCap / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| Price / BV (X) | 0.83 | 1.14 | 0.89 | -1.87 | -2.65 |
| Price / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| EarningsYield | 0.05 | 0.04 | 0.71 | -0.21 | -0.40 |
After reviewing the key financial ratios for Cravatex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.40. This value is within the healthy range. It has decreased from 25.97 (Mar 24) to 24.40, marking a decrease of 1.57.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 672.41. It has decreased from 784.12 (Mar 24) to 672.41, marking a decrease of 111.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.94. This value is within the healthy range. It has decreased from 32.66 (Mar 24) to 31.94, marking a decrease of 0.72.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.22. This value is within the healthy range. It has increased from 25.37 (Mar 24) to 26.22, marking an increase of 0.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.84 (Mar 24) to 24.66, marking an increase of 0.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For PBDIT Margin (%), as of Mar 25, the value is 4.75. This value is below the healthy minimum of 10. It has increased from 4.16 (Mar 24) to 4.75, marking an increase of 0.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from 3.23 (Mar 24) to 3.90, marking an increase of 0.67.
- For PBT Margin (%), as of Mar 25, the value is 3.66. This value is below the healthy minimum of 10. It has increased from 3.04 (Mar 24) to 3.66, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 5. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 8. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.53. This value is below the healthy minimum of 15. It has decreased from 4.89 (Mar 24) to 4.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.18. This value is below the healthy minimum of 10. It has decreased from 6.42 (Mar 24) to 6.18, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 3.43. This value is below the healthy minimum of 5. It has decreased from 3.87 (Mar 24) to 3.43, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.31. It has decreased from 1.55 (Mar 24) to 1.31, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 4.22. This value exceeds the healthy maximum of 3. It has decreased from 5.11 (Mar 24) to 4.22, marking a decrease of 0.89.
- For Quick Ratio (X), as of Mar 25, the value is 3.86. This value exceeds the healthy maximum of 2. It has decreased from 4.64 (Mar 24) to 3.86, marking a decrease of 0.78.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.69. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 15.69, marking an increase of 15.69.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.39. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 20.39, marking a decrease of 0.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 13.18 (Mar 24) to 12.93, marking a decrease of 0.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.09. It has decreased from 36.92 (Mar 24) to 13.09, marking a decrease of 23.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 0.18 (Mar 24) to 0.07, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.59, marking a decrease of 2.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.14 (Mar 24) to 0.83, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cravatex Ltd:
- Net Profit Margin: 2.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.18% (Industry Average ROCE: 15.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.53% (Industry Average ROE: 8.86%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.86
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.7 (Industry average Stock P/E: 90.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.77%
Cravatex Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | 1st Floor, Godrej Bhavan, 4A Home Street Mumbai Maharashtra 400001 | investors@cravatex.com http://www.cravatex.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Batra | Chairman & Managing Director |
| Mr. Divakar G Kamath | Executive Director & CFO |
| Mr. Rohan Batra | Non Executive Director |
| Mr. Pheroza Jimmy Bilimoria | Independent Director |
| Mr. Satyan Shivkumar Israni | Independent Director |
| Mr. Nakul Toshniwal | Independent Director |
FAQ
What is the intrinsic value of Cravatex Ltd?
Cravatex Ltd's intrinsic value (as of 07 December 2025) is 298.44 which is 21.46% lower the current market price of 380.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 98.0 Cr. market cap, FY2025-2026 high/low of 555/310, reserves of ₹104 Cr, and liabilities of 141 Cr.
What is the Market Cap of Cravatex Ltd?
The Market Cap of Cravatex Ltd is 98.0 Cr..
What is the current Stock Price of Cravatex Ltd as on 07 December 2025?
The current stock price of Cravatex Ltd as on 07 December 2025 is 380.
What is the High / Low of Cravatex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cravatex Ltd stocks is 555/310.
What is the Stock P/E of Cravatex Ltd?
The Stock P/E of Cravatex Ltd is 17.7.
What is the Book Value of Cravatex Ltd?
The Book Value of Cravatex Ltd is 436.
What is the Dividend Yield of Cravatex Ltd?
The Dividend Yield of Cravatex Ltd is 3.29 %.
What is the ROCE of Cravatex Ltd?
The ROCE of Cravatex Ltd is 6.57 %.
What is the ROE of Cravatex Ltd?
The ROE of Cravatex Ltd is 4.68 %.
What is the Face Value of Cravatex Ltd?
The Face Value of Cravatex Ltd is 10.0.